Kailera Therapeutics Raises $600 Million
Investors have announced a significant private financing round for biotech company Kailera Therapeutics, pouring $600 million into the obesity drug startup.
The financing was led by Bain Capital's private equity group and included Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada's national pension plan, as well as several of Kailera's founding investors.
This deal highlights the ongoing interest in weight loss drugs, despite some clinical disappointments in recent years.
Kailera's Series B round comes almost exactly one year after the startup launched with $400 million, and shortly after Pfizer announced plans to buy another privately held obesity drug developer, Metsera, for $4.9 billion.
The deal underlines the persistent heightened attention being paid to weight loss drugs.
Author's summary: Kailera Therapeutics raises $600 million in financing.